C-EHRN highlights shifting drug trends across Europe, noting the rising prevalence of polydrug use, potent synthetic substances, and the critical need for adapted harm reduction services.
The Drug Policy Alliance says shifting from fear-based narratives to positive, public health messaging is key to building safer and healthier communities.
Mainline's closure due to loss of international and domestic funding highlights growing concerns over the sustainability of harm reduction services globally.
The report outlines key barriers to harm reduction in Africa and proposes rights-based, community-led strategies to expand access, strengthen systems, and ensure sustainable, evidence-based responses.
The INCB examines mounting pressures on the global drug control system, from synthetic drugs and access to medicines to increasing fragmentation within the Commission on Narcotic Drugs.
Outgoing IDPC Executive Director, Ann Fordham reflects on the evolution of global drug policy, the growth of civil society advocacy, and the urgent need to defend hard-won progress.
In her final CND as IDPC ED, Ann Fordham reflects on a historic shift: the recognition of harm reduction in UN drug policy debates, amid rising geopolitical tensions, fractured consensus, and a multilateral system under strain.
IDPC welcomes Resolution 60/26 as a landmark affirmation of the Council's authority to address the human rights implications of drug policy, strengthening the UN human rights system and reinforcing calls for health-, rights- and evidence-based drug policies globally.
A new McGill University study finds that Toronto’s supervised drug consumption sites were not linked to rising crime — and in most cases, crime declined over time.
